Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 314
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT02605993 | Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT00739505 | Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP) | ||
| NCT02306720 | Registry of Patients With Hypophosphatasia | ||
| NCT01180790 | Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants | ||
| NCT06208488 | A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector in Healthy Adult Participants | ||
| NCT02496689 | Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP) | ||
| NCT00952484 | Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP) | ||
| NCT04469465 | Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA) | ||
| NCT05314231 | Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria | ||
| NCT06312644 | Study of Ultomiris® (Ravulizumab) Safety in Pregnancy | ||
| NCT03131219 | Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) | ||
| NCT01221181 | Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy | ||
| NCT03369236 | A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) | ||
| NCT04920370 | Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects | ||
| NCT00844428 | Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS | ||
| NCT04201262 | An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD | ||
| NCT01755429 | To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients | ||
| NCT01633489 | Lysosomal Acid Lipase (LAL) Deficiency Registry | ||
| NCT01410916 | Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS) | ||
| NCT04933682 | Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants | ||
| NCT03397888 | The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist | ||
| NCT05303324 | Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults | ||
| NCT04610580 | Bioavailability Study of 2 Oral Formulations of ALXN1840 | ||
| NCT04526210 | Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants | ||
| NCT03766347 | Pediatric NMOSD Observational Study | ||
| NCT03748823 | Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab | ||
| NCT02145182 | Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study) | ||
| NCT04609696 | Study of the Metabolism of Danicopan in Healthy Adults | ||
| NCT04256148 | ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia | ||
| NCT05319899 | A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults | ||
| NCT01335165 | Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT01095887 | Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation | ||
| NCT01765855 | An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy Male Subjects | ||
| NCT04195763 | Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa) | ||
| NCT03384186 | A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants | ||
| NCT02090179 | Evaluation of Blood Brain Barrier Integrity and Structural Abnormalities in MPS IIIB Patients Using Multimodal Magnetic Resonance Imaging | ||
| NCT01583218 | Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study) | ||
| NCT04422431 | Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840 | ||
| NCT01892345 | A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study) | ||
| NCT02245412 | A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease | ||
| NCT00122330 | Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients | ||
| NCT01765868 | A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers | ||
| NCT02372513 | National Lysosomal Acid Lipase Deficiency Study | ||
| NCT04543591 | Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant | ||
| NCT05556096 | Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis | ||
| NCT01994382 | Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL | ||
| NCT05982938 | Danicopan Early Access Program | ||
| NCT05047458 | A Study of Single-dose ALXN2050 in Healthy Adults | ||
| NCT02376751 | An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency | ||
| NCT00122304 | Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab |
